In January 2025, Scientific Reports published an observational pilot study evaluating the long-term efficacy and safety of entecavir (ETV) versus tenofovir alafenamide (TAF) in patients with chronic hepatitis B.
Key Findings:
After 240 weeks, both drugs showed comparable reductions in hepatitis B surface antigen and core-related antigen levels.
Renal safety profiles were similar, with no significant differences in eGFR, urinary β2-microglobulin/creatinine, or N-acetyl-β-D-glucosaminidase/creatinine ratios.
The incidence of hepatocellular carcinoma (HCC) did not differ significantly between the groups (p = 0.08).
Long-term treatment with ETV and TAF offers similar efficacy and safety profiles in managing chronic hepatitis B, with no significant differences in HCC risk.
